Chenguang Biotech Group (300138) - Total Liabilities
Based on the latest financial reports, Chenguang Biotech Group (300138) has total liabilities worth CN¥4.57 Billion CNY (≈ $669.18 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Chenguang Biotech Group (300138) long-term investment share to see how much of total assets are deployed in long-term investments.
Chenguang Biotech Group - Total Liabilities Trend (2007–2024)
This chart illustrates how Chenguang Biotech Group's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 300138 asset base.
Chenguang Biotech Group Competitors by Total Liabilities
The table below lists competitors of Chenguang Biotech Group ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Asseco Business Solutions S.A.
WAR:ABS
|
Poland | zł138.21 Million |
|
Ardmore Shpng
NYSE:ASC
|
USA | $154.39 Million |
|
HIVE Digital Technologies Ltd
NASDAQ:HIVE
|
USA | $109.79 Million |
|
ChengDa Pharmaceuticals Co. Ltd.
SHE:301201
|
China | CN¥251.32 Million |
|
Shanxi Zhendong Pharmaceutical
SHE:300158
|
China | CN¥882.65 Million |
|
Sgis Songshan Co Ltd
SHE:000717
|
China | CN¥12.19 Billion |
|
Zhe Jiang Kangsheng Co Ltd
SHE:002418
|
China | CN¥1.62 Billion |
|
Ganesh Housing Corporation Limited
NSE:GANESHHOUC
|
India | Rs2.82 Billion |
Liability Composition Analysis (2007–2024)
This chart breaks down Chenguang Biotech Group's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Chenguang Biotech Group net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chenguang Biotech Group's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chenguang Biotech Group (2007–2024)
The table below shows the annual total liabilities of Chenguang Biotech Group from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥5.87 Billion ≈ $858.65 Million |
+17.18% |
| 2023-12-31 | CN¥5.01 Billion ≈ $732.73 Million |
+34.98% |
| 2022-12-31 | CN¥3.71 Billion ≈ $542.84 Million |
+16.96% |
| 2021-12-31 | CN¥3.17 Billion ≈ $464.13 Million |
+22.23% |
| 2020-12-31 | CN¥2.59 Billion ≈ $379.72 Million |
-6.18% |
| 2019-12-31 | CN¥2.77 Billion ≈ $404.75 Million |
+71.07% |
| 2018-12-31 | CN¥1.62 Billion ≈ $236.61 Million |
+29.47% |
| 2017-12-31 | CN¥1.25 Billion ≈ $182.75 Million |
+29.09% |
| 2016-12-31 | CN¥967.46 Million ≈ $141.57 Million |
+71.50% |
| 2015-12-31 | CN¥564.12 Million ≈ $82.55 Million |
+12.89% |
| 2014-12-31 | CN¥499.69 Million ≈ $73.12 Million |
-22.08% |
| 2013-12-31 | CN¥641.26 Million ≈ $93.84 Million |
+43.23% |
| 2012-12-31 | CN¥447.73 Million ≈ $65.52 Million |
+204.24% |
| 2011-12-31 | CN¥147.16 Million ≈ $21.53 Million |
-31.84% |
| 2010-12-31 | CN¥215.92 Million ≈ $31.60 Million |
+12.36% |
| 2009-12-31 | CN¥192.17 Million ≈ $28.12 Million |
-19.02% |
| 2008-12-31 | CN¥237.31 Million ≈ $34.73 Million |
+177.57% |
| 2007-12-31 | CN¥85.49 Million ≈ $12.51 Million |
-- |
About Chenguang Biotech Group
ChenGuang Biotech Group Co., Ltd. develops and produces natural colors, spice extracts and essential oils, nutritional and pharmaceutical extracts, and oils and protein. The company offers natural colors, including paprika oleoresin, marigold oleoresin, and turmeric; spice extracts and essential oils, such as capsicum oleoresin, sichuan pepper oil, pepper oleoresin, ginger extract, and cumin oleo… Read more